Soft Drugs. XX. Design, Synthesis, and Evaluation of Ultra-Short Acting Beta-Blockers

Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists

Volumn 12, Issue 3, 1995, Pages 329-336

  Yang, Hee Sun ^a   Wu, Whei Mei ^a   Bodor, Nicholas ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

inactive metabolite approach; metoprolol; soft drugs; ultra short acting blockers

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG METABOLITE; ESMOLOL; METOPROLOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG DESIGN; DRUG HYDROLYSIS; DRUG SYNTHESIS; ESTERIFICATION; HUMAN; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RABBIT; RAT; TACHYCARDIA;

ADRENERGIC BETA-ANTAGONISTS; ANIMAL; DRUG DESIGN; ESTERS; HYDROGEN-ION CONCENTRATION; MALE; PHARMACEUTICAL PREPARATIONS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0028907497     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1023/A:1016283930696     Document Type: Article

References (29)

1. Labetalol Therapy in Patients With Systemic Hypertension and Angina Pectoris: Effects of Combined Alpha and Beta Adrenoceptor Blockade
2. Beta-Adrenergic Blocking Drugs
3. Adrenoceptor Blocking Drugs: Clinical Pharmacology and Therapeutic Use
4. Adverse Reactions to β-Adrenergic Receptor Blocking Drugs: A Report from Boston Collaborative Drug Surveillance Program
5. Adverse Effects of β-Adrenergic Receptor Blocking Drugs on Respiratory Function
6. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a β-adrenoceptor blocker
7. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Adverse effects. Choosing a β-adrenoceptor blocker
8. Controlled Beta-receptor Blockade with Esmolol and Flestolol
9. Ultra-Short-Acting β-Adrenergic Blockers
10. Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blockers
11. β-Adrenoceptor Activity of the Stereoisomer of the Bufuraolol Alcohol and Ketone Metabolites
12. Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site Specific Chemical Delivery System
13. Soft Drugs. 7. Soft β-Blockers for Systemic and Ophthalmic Use
14. Ultra-Short-Acting β-Adrenergic Blocking Agent. 1. (Aryloxy)propanolamines Containing Esters in the Nitrogen Substituent
15. Ultra-Short-Acting β-Adrenergic Blocking Agent. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function
16. Improved Delivery through Biological Membranes IX: Kinetics and Metabolism of Hydrolysis of Methylsulfinylmethyl 2-Acetoxybenzoate and Related Aspirin Prodrugs
17. Improved Delivery through Biological Membranes X: Percutaneous Absorption and Metabolism of Methylsulfinylmethyl 2-Acetoxybenzoate and Related Aspirin Prodrugs
18. Esmolol: A Titratable Short-Acting Intravenous Beta-Blocker for Acute Critical Care Settings
19. Esmolol. A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy
20. Esmolol hydrochloride: An ultrashort-acting, β-adrenergic blocking agent
21. Protection of Carboxylic Acids as Methylthiomethyl Esters
22. Metabolism of Metoprolol in the Rat in vitro and in vivo
23. Improved Delivery through Biological Membranes VIII: Design, Synthesis, and In Vivo Testing of True Prodrugs of Aspirin
24. Biochemical Properties of Blood Esmolol Esterase
25. Esmolol
26. Esmolol: A Titratable Short-Acting Intravenous Beta-Blocker for Acute Critical Care Setting